- Home
- QFIN vs PTGX Comparison
QFIN vs PTGX Comparison
Compare QFIN & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QFIN
- PTGX
- Stock Information
- Founded
- QFIN 2016
- PTGX 2006
- Country
- QFIN China
- PTGX United States
- Employees
- QFIN 3527
- PTGX N/A
- Industry
- QFIN Finance: Consumer Services
- PTGX Biotechnology: Pharmaceutical Preparations
- Sector
- QFIN Finance
- PTGX Health Care
- Exchange
- QFIN Nasdaq
- PTGX Nasdaq
- Market Cap
- QFIN 4.0B
- PTGX 4.0B
- IPO Year
- QFIN 2018
- PTGX 2016
- Fundamental
- Price
- QFIN $28.53
- PTGX $65.16
- Analyst Decision
- QFIN Strong Buy
- PTGX Strong Buy
- Analyst Count
- QFIN 2
- PTGX 8
- Target Price
- QFIN $45.10
- PTGX $71.13
- AVG Volume (30 Days)
- QFIN 1.8M
- PTGX 1.0M
- Earning Date
- QFIN 11-18-2025
- PTGX 11-06-2025
- Dividend Yield
- QFIN 5.38%
- PTGX N/A
- EPS Growth
- QFIN 68.82
- PTGX N/A
- EPS
- QFIN 7.06
- PTGX 0.80
- Revenue
- QFIN $2,618,582,596.00
- PTGX $209,180,000.00
- Revenue This Year
- QFIN $17.67
- PTGX N/A
- Revenue Next Year
- QFIN $6.25
- PTGX $248.17
- P/E Ratio
- QFIN $4.29
- PTGX $81.41
- Revenue Growth
- QFIN 9.77
- PTGX N/A
- 52 Week Low
- QFIN $27.64
- PTGX $33.31
- 52 Week High
- QFIN $48.94
- PTGX $68.26
- Technical
- Relative Strength Index (RSI)
- QFIN 44.09
- PTGX 60.49
- Support Level
- QFIN $28.29
- PTGX $62.24
- Resistance Level
- QFIN $31.08
- PTGX $66.87
- Average True Range (ATR)
- QFIN 1.29
- PTGX 2.36
- MACD
- QFIN 0.04
- PTGX -0.16
- Stochastic Oscillator
- QFIN 15.00
- PTGX 62.42
About QFIN Qifu Technology Inc.
Qfin Holdings Inc Formerly Qifu Technology Inc is a Credit-Tech platform in China. It provides credit services more accessible and personalized to consumers and SMEs through Credit-Tech services to financial institutions, whereby it deploys its technology solutions to help financial institutions identify the diversified needs of consumers and SMEs, effectively access prospective borrowers that are creditworthy through multi-channels, enhance credit assessment on prospective borrowers, and manage credit risks and improve collection strategies and efficiency, among others.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.